From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development
Clinical and Translational Science · 2026-10 · 19 (10)
DOI: 10.1111/cts.70734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 30.09.2026. Verfasst von Mareena Biju und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Development, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors. This study used U.S. Optum claims data from 2019 to 2024 to characterize co‐medication patterns in predominately non‐small cell lung cancer (NSCLC) patients and map enzyme‐ and transporter‐mediated liabilities across commonly used medications, chemotherapy agents, and biomarker‐driven therapies. Potential DDI liabilities were further prioritized using a semi‐quantitative clinical framework based on perpetrator strength, substrate sensitivity, narrow therapeutic index status, and available evidence. Frequently used medications included disease‐specific supportive therapies such as ondansetron and dexamethasone, as well as treatments for common U.S. comorbidities such as cardiovascular and endocrine disorders. Many of the co‐medications were substrates, inhibitors, and inducers of pathways critical for NSCLC treatments such as CYP3A, CYP2D6, P‐gp, and OATP1B and additional risks were identified when giving treatments with acid‐reducing agents or QT‐prolonging drugs. These findings demonstrate how integrating real‐world data (RWD) can strengthen DDI assessment by improving clinical trial design, informing risk‐mitigation strategies, and supporting more patient‐centric drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
- Astellas Pharma US, Illinois, USA.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
ORCID-Profile: Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang
Zitieren
APA
Biju, M., Choi, H., Madari, S., Carlisle, A., Sharma, A., Kunz, C., & Huang, F. (2026). From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development. Clinical and Translational Science, 19(10). https://doi.org/10.1111/cts.70734
Vancouver
Biju M, Choi H, Madari S, Carlisle A, Sharma A, Kunz C, et al. From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development. Clinical and Translational Science. 2026;19(10). doi:10.1111/cts.70734
BibTeX
@article{Biju2026,
author = {Biju, Mareena and Choi, HeeJae and Madari, Shilpa and Carlisle, Annie and Sharma, Ashish and Kunz, Christina and Huang, Fenglei},
title = {From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {10},
doi = {10.1111/cts.70734}
}
EUVIMED